ArticleBreast cancer research and treatment2025
BRCA testing utilization among commercially insured women with breast or ovarian cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis report examines utilization of germline BRCA genetic testing among women with breast or ovarian cancer in the context of current clinical guidelines for testing.
methodsLinked IQVIA commercial claims and electronic medical record data were used to analyze BRCA test utilization among women aged 18-64 years with newly diagnosed breast cancer or ovarian cancer during 2016-2021, excluding 2018. Log-binomial regression models were used to estimate prevalence ratios (PRs) comparing utilization of testing by cancer type, age group, race, and year.
resultsAmong commercially insured women with newly diagnosed breast cancer (n = 19,139) or epithelial ovarian cancer (n = 1639), 50 and 47%, respectively, received germline BRCA testing during the study years. BRCA testing rates were higher among women with breast cancer aged 18-50 years (69%) compared to those aged 51-64 years (39%). Overall utilization among women with breast or ovarian cancer was slightly lower in 2021 compared to 2019 and 2020. Compared with White women with breast cancer, Asian women were less likely (PR, 0.83 [95% CI, 0.74-0.92]) to receive testing.
conclusionNearly one-third of women who had breast cancer at age 50 or younger and a majority of women with ovarian cancer had no germline BRCA testing recorded within 1 year of diagnosis. Under current (2024) guidelines, these women and their family members are eligible for genetic counseling and testing to guide preventive interventions for future cancers. Healthcare providers have an important role in offering genetic services to women and their families, ensuring that eligible women receive recommended care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.